Close
What would you like to look for?
Site search
Search filters

Proteomedix AG licenses manufacturing IP to Immunovia AB

24 September 2025

VISCHER advised Proteomedix AG, a Swiss biotech subsidiary of Onconetix, Inc., on a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company.

Medartis acquires remaining 53% of KeriMedical

10 September 2025

Medartis (SIX: MED), an orthopedic company based in Basel specializing in head and extremity surgery, has acquired the remaining 53% of Geneva-based KeriMedical SA and is now the sole owner of the company.

AutoScout24 integrates the C2B business from CARAUKTION

9 September 2025

VISCHER advised CARAUKTION on the takeover of the C2B business division, including the C2B auction platform, by AutoScout24.

Schivo acquires Mecaplast SA

4 September 2025

VISCHER advised Schivo on the acquisition of Mecaplast SA.

VISCHER advised LOOMIS AB in its acquisition of Kipfer Logistik GmbH

12 August 2025

VISCHER advised LOOMIS AB in its acquisition of Kipfer Logistik GmbH, a Switzerland-based logistics company specializing in temperature-controlled transport and storage in the pharmaceutical sector.

Claraspital Basel is being acquired by University Hospital Basel

4 August 2025

The University Hospital Basel (USB), one of Switzerland's leading university hospitals, is acquiring St. Claraspital AG, a leading, systemically important hospital in north-western Switzerland, from St. Clara AG and the Ingenbohl Monastery.

VISCHER advises Basel-Stadt on the implementation of the ESC

31 July 2025

VISCHER provided comprehensive legal advice to the Canton of Basel-Stadt on the implementation of the Eurovision Song Contest 2025.

VISCHER advises Basel-Stadt on hosting the UEFA Women’s EURO 2025

29 July 2025

VISCHER provided comprehensive legal advice and support to Basel-Stadt in hosting the UEFA Women's EURO 2025.

VISCHER advises Primeo Energie, Groupe E and ewb on the sale of MOVE

11 July 2025

Primeo Energie, Groupe E and ewb sell MOVE Mobility.

Nuclidium AG closes Series B financing round

10 July 2025

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, announced the successful closing of its Series B financing round, raising CHF 79m (EUR 84m).